In a randomized double-blind placebo-controlled clinical trial of 48 SLE patients (NCT00710021), cholecalciferol supplementation did not significantly decrease IFN signature, defined by the expression levels of IFN-induced genes related to disease activity [122]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.